Buscar
Urogen Pharma Ltd
URGNAñadir a la lista de seguimiento
38.240USD
-2.850-6.94%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.86BCap. mercado
PérdidaP/E TTM
Más Datos de Urogen Pharma Ltd Compañía
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Información de Urogen Pharma Ltd
Símbolo de cotizaciónURGN
Nombre de la empresaUrogen Pharma Ltd
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoBarrett (Elizabeth A)
Número de empleados235
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección9 Ha'ta'asiya St
CiudadRA'ANANA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal4365007
Teléfono97297707601
Sitio Webhttps://www.urogen.com/
Símbolo de cotizaciónURGN
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoBarrett (Elizabeth A)
Ejecutivos de Urogen Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Urogen Pharma Ltd?
Los cinco principales accionistas de Urogen Pharma Ltd son: Dr. Arie S. Belldegrun, M.D.
¿Cuántas instituciones poseen acciones de Urogen Pharma Ltd (URGN)?
A fecha de 2026Q1, 349 instituciones poseen acciones de Urogen Pharma Ltd, con un valor de mercado combinado de aproximadamente 46.29M, lo que representa el 95.00% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -15691017.00.
¿Cuál es la mayor fuente de ganancias de Urogen Pharma Ltd?
El 2026Q1, el segmento empresarial Jelmyto generó la ganancia más alta para Urogen Pharma Ltd, ascendiendo a 93.99M y representando el 85.61% de la ganancia total.